rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
National Center for Geriatrics and Gerontology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are 65 years of age or older and have a confirmed diagnosis of RA based on the ACR Rheumatoid Arthritis Classification Criteria 1987 or ACR/EULAR Rheumatoid Arthritis Classification Criteria 2010. Patients provide written informed consent and are eligible 1) or 2). 1) Patients who have never been treated with anti-rheumatic drugs and started anti-rheumatic drug therapy for the first time during the registration period (January 2022 to December 2023). 2) Patients who have been treated with anti-rheumatic drugs and started MTX or molecular targeted drugs (for the first drug) time during the registration period. Patients who have already started treatment with anti-rheumatic drugs at other medical institutions may be enrolled within 30 days of the start of treatment.
Exclusion criteria
Exclusion criteria: 1) Patients who are unable to give consent to participate in the research 2) Patients who have already received treatment with any of the molecular targeted drugs covered by insurance for rheumatoid arthritis. 3) Patients with systemic autoimmune disease complications other than Sjogren's syndrome. 4) Other patients deemed inappropriate for inclusion by the investigators or others.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Factors related to survival and cause of death 2) Factors related to hospitalization (malignancy, infection, cardiovascular events, fracture and pneumonia) 3) Prevalence of requiring long-term care and their grade 4) Changes in QOL (EQ-5D-5L) and factors related to the decline in QOL 5) Changes in physical function (HAQ) and factors related to decline in physical function | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Trends in frailty and sarcopenia 2) Changes in physical functions other than HAQ and factors related to the decline in physical functions 3) Changes in cognitive function and factors related to decline in cognitive function 4) Changes in disease activity 5) Changes in joint destruction 6) Changes in Patient-reported Outcome 7) Whether MTX is administered, the dose and interval, if not, reasons for dose increase, decrease, or discontinuation 8) Whether or not molecularly targeted drugs are administered, and reasons for prolonging the interval, reducing the dose, or discontinuing. 9) GCs administration or not, dose, and reasons for dose increase or decrease or discontinuation 10) Whether or not NSAIDs are administered | — |
Countries
Japan
Contacts
Public ContactMikako Yasuoka
National Center for Geriatrics and Gerontology Center for Gerontology and Social Science
Outcome results
None listed